Plasmodium falciparum causes the severe form of malaria that has high levels of mortality in humans. Blood-stage merozoites of P. falciparuminvade erythrocytes, and this requires interactions between multiple ligands from the parasite and receptors in hosts. These interactions include the binding of the Rh5–CyRPA–Ripr complex with the erythrocyte receptor basigin1,2, which is […]
The quest to develop an effective malaria vaccine remains a major priority in the fight against global infectious disease. An approach with great potential is a transmission-blocking vaccine which induces antibodies that prevent establishment of a productive infection in mosquitos that feed on infected humans, thereby stopping the transmission cycle. […]
Plasmodium falciparum reticulocyte-binding protein homolog 5 (PfRH5) is a leading asexual blood-stage vaccine candidate for malaria. In preparation for clinical trials, a full-length PfRH5 protein vaccine called “RH5.1” was produced as a soluble product under cGMP using the ExpreS2 platform (based on a Drosophila melanogaster S2 stable cell line system). […]
ExpreS2ion Biotechnologies will be presenting at the ISBiotech 8th Spring Meeting taking place on March 5-7, 2018 in Norfolk, Virginia, USA. The presentation is titled “HER2 Cancer Vaccine Optimization by Combining Drosophila S2 Insect Cell Manufacturing with a Novel VLP-Display Technology”. The speaker is Dr. Wian de Jongh, CSO, ExpreS2ion […]
ExpreS2ion Biotechnologies and AdaptVac will be presenting at the free webinar on March 14 at 5PM CET / 4PM GMT / 12PM EDT / 9AM PDT, hosted by the leading science journal published by Elsevier, Vaccine. The webinar is titled “Developing a HER2-VLP vaccine for treatment of HER2-positive cancer; optimizing […]
Expres2ion Biotechnologies is mentioned in the Swedish newspaper Affärstidningen Näringsliv, in the supplement section “Time to Unite – a Greater Medicon Valley”. The article with the headline “Using insect cells in biotechnology for better protein production” can be seen on page 13 on the link to the interactive web version […]
ExpreS2ion Biotechnologies is the topic of an article (in Danish) in the business journal MedWatch under the headline “ExpreS2ion-direktør efter første fulde regnskabsår: “Vi står i en unik position til at ekspandere” ”. he article includes an interview with CEO Steen Klysner. The article can be seen on https://medwatch.dk/secure/Medicinal___Biotek/article10287938.ece
Horsholm, Denmark, November 8, 2017 – Today, ExpreS2ion Biotechnologies ApS (“ExpreS2ion”), a fully owned subsidiary of ExpreS2ion Biotech Holding AB, announces that University of Pennsylvania, Philadelphia, USA, has signed a Research License Agreement granting University of Pennsylvania the right to conduct research using ExpreS2ion’s proprietary protein expression system, ExpreS2. The […]
Expres2ion Biotechnologies is the topic of an article (in Danish) in the business journal MedWatch under the headline “Biotekselskab og KU-spinout i ambitiøst vaccinesamarbejde”. The article includes an interview with CEO Steen Klysner. The article can be seen on http://medwatch.dk/Medicinal___Biotek/article9687521.ece
Horsholm, Denmark, June 26, 2017 – Today, ExpreS2ion Biotechnologies ApS (“ExpreS2ion”), a fully owned subsidiary of ExpreS2ion Biotech Holding AB, announces that the Francis Crick Institute, London, United Kingdom, has agreed to amend the Research License Agreement about ExpreS2ion’s proprietary ExpreS2 expression system for another year. The Research License Agreement […]
